|
May 15
|
BeiGene (NasdaqGS:ONC) Reveals Promising Phase 1 Trial Results Across Multiple Cancer Studies
|
|
May 14
|
BeiGene Showcases Strength of Hematology Portfolio at EHA 2025 with New Data Highlighting BRUKINSA’s Leadership and Next-Generation Innovation
|
|
Apr 17
|
BeiGene to Announce First Quarter 2025 Financial Results on May 7
|
|
Feb 17
|
HRMY or ONC: Which Is the Better Value Stock Right Now?
|
|
Feb 13
|
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
|
|
Feb 12
|
Is There An Opportunity With BeiGene, Ltd.'s (NASDAQ:ONC) 41% Undervaluation?
|
|
Dec 30
|
BeiGene’s Tevimbra approved in US for first-line gastric cancer treatment
|